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Abstract
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare and severe hereditary skin disease. Oligoarticular
Juvenile Idiopathic Arthritis (JIA) although infrequent in the general paediatric population, is the most frequent
type of autoimmune joint disease in children. While different in aetiology, both diseases are characterized by
gradual deterioration in mobility and function. We report a female patient, diagnosed with RDEB at birth, who
presented with inflammatory bowel disease (IBD) at the age of four years, and subsequently developed
oligoarticular JIA at seven years of age, and discuss the diagnostic and treatment challenges of this unusual case.
This report, besides presenting a unique case, also highlights the important issues that need to be taken into
account when assessing and managing patients with such complex conditions.
Introduction
Recessive Dystrophic Epidermolysis Bullosa (RBED) is a
rare and severe genetically determined disorder charac-
terized by excessive susceptibility of the skin and muco-
sae to separate from the underlying tissues following
mechanical trauma. Conversely, oligoarticular JIA is the
commonest form of auto-immune arthritis in childhood.
Both diseases are characterized by severe limitation of
mobility and loss of function. Although the autoimmune
bullous skin disease Epidermolysis Bullosa Aquisita
(EBA) has been linked with other autoimmune condi-
tions such as IBD, systemic lupus erythematosus, Hashi-
moto’s thyroiditis and amyloidosis, there has not been
any previous report of severe generalized RDEB asso-
ciated with autoimmune conditions, such as arthritis.
Case report
Our patient was diagnosed with severe generalized
RDEB shortly after birth on the basis of complete
absence of type VII collagen and a sublamina densa split
on electron microscopy of a skin biopsy. By the age of 4
years she developed abdominal distension and severe
diarrhoea. Screen for celiac disease, food specific allergy
tests (IgE’s), and stool microscopy and culture were
negative. An upper and lower gastrointestinal endoscopy
and biopsy revealed the presence of an extensive yet
non-classical colitis in keeping with unclassified inflam-
matory bowel disease. She was treated with a restrictive
diet excluding dairy, wheat and soya and she was put on
a modified feed. Sulfasalazine (1 gr/day) and low dose
prednisolone (0.5 mg/kg/day) were added to try to con-
trol her bowel symptoms. Over time, chronic wounds
due to her RDEB healed with atrophic scaring, and joint
contractures developed despite regular physiotherapy,
resulting in significant loss of mobility and function. At
the age of 7 years she developed persistent localized
pain in the right hip joint, associated with morning stiff-
ness, antalgic position and rapid deterioration of func-
tion in that limb. Plain radiography of the hips showed
erosive changes and loss of intra-articular joint space;
MRI with gadolinium showed active inflammation with
synovial thickening, cortical irregularity, loss of cartilage
and subcortical oedema on the right and chronic
changes on the left hip joint (Figure 1). She had mild
microcytic anemia; ESR and CRP were moderately ele-
vated. Anti-nuclear antibodies (ANA) titers were posi-
tive at 1:640 and she tested negative for HLA B-27.
Screen for uveitis was negative. At this point this was
considered a monoarthritis as the chronic changes seen
on the left could be attributed to either previous disease
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biopsy to exclude any other pathology would have been
optimal. However, we faced a dilemma as whether to
proceed with this invasive procedure in view of her
extensive chronic skin erosions with high risk of infec-
tion as well as increased mortality risks of generalized
anaesthesia in this group of patients [1,2]. The diagnosis
of oligoarticular JIA was therefore based on clinical,
laboratory and radiological findings. She was then trea-
ted with intra-articular joint injection (IAI) with steroids
under USS guidance. Fluid aspirated was sterile for
pathogens including mycobacterium tuberculosis.
A year following diagnosis, she presented with arthritis
involving both knees and right hip; meanwhile her
bowel symptoms were incompletely controlled; nutrition
was suboptimal (weight: < 5
th centile, height: 10
th cen-
tile), and she required intensive dietitian support.
Her arthritis was treated with IAI with triamcinolone
hexacetonide; she was started on oral methotrexate (15
mg/m
2/week) that failed to control her disease. In view
of the partially controlled colitis and progressive arthritis
we decided to commence anti-TNF-a treatment. Adali-
mumab (20 mg/fortnightly) and methotrexate (15 mg/
m
2/week) both administered subcutaneously were cho-
sen since the risk of sepsis precluded a permanent line
and venous access was extremely difficult.
The combination of adalimumab and methotrexate
has controlled both her arthritis and inflammatory
bowel disease and she remained symptom free two years
following initiation of treatment. In addition there was
also a clinical improvement of her skin, with fewer
chronically eroded areas and less marked chronic anae-
mia. Inflammatory markers and ANA titers improved.
She subsequently developed two flares of her arthritis
with no associated bowel symptoms, which was treated
with IAI followed by physiotherapy and rehabilitation.
Her nutritional status is satisfactory (weight and height:
>1 0
th centile).
Discussion
Epidermolysis bullosa can broadly be separated into 4
major types and numerous subtypes according to the
Figure 1 MRI Scan of the Patient. MRI with gadolinium showing active inflammation with synovial thickening, cortical irregularity, loss of
cartilage and subcortical oedema on the right hip joint and chronic changes on the left hip joint.
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pattern of involvement and clinical severity. Severe gen-
eralized RDEB (previously known as Hallopeau-Siemens)
is one of the most severe forms with an overall mortality
rate of 8% during childhood [2]. The most common
reported causes of death in childhood include sepsis and
severe failure to thrive, while in the adolescent and
adult population cutaneous squamous cell carcinoma
accounts for the substantial majority of deaths, usually
in the third to fifth decades. Other less common causes
of death include renal failure and cardiomyopathy. Mul-
tidisciplinary care with early treatment of infections,
optimizing nutrition and a wide variety of supporting
services has improved the quality of life and survival
rates over the past decade [3].
Nevertheless, clinical assessment and management of
these patients remains challenging, especially as in our
case additional nosological entities complicate the
course of their illness. The presentation of persistent hip
p a i ni nap r e v i o u s l yh e a l t h yc h i l dc a np o s ead i a g n o s t i c
dilemma with oligoarticular JIA being one of the possi-
ble diagnoses. In our patient there was a delay from
initial onset of symptoms to establishing the diagnosis.
Pain is also inevitable with this severe type of EB
coupled with limitation of mobility from contractions
and skin wounds. Additionally, the treatment with pre-
dnisolone and sulfasalazine for her IBD and regular use
of NSAID for analgesia may have masked a more strik-
ing presentation. IBD arthropathy could be the cause of
her joint symptoms; however the persistent oligoarticu-
lar pattern of presentation, the destructive form of
arthritis, and the high ANA titers pointed towards a dis-
tinct diagnosis of JIA. Additionally, joint flare-ups per-
sisted while bowel disease was in remission [4].
The routine approach to any patient presenting with
monoarthritis of the hip would include synovial fluid
aspiration +/- synovial biopsy. In this case the increased
risk of secondary septic arthritis or sepsis in general pre-
cluded any intervention other than a therapeutic one;
diagnosis was based on clinical and radiological findings
alone.
With regards to treatment, although our patient had a
common form of JIA, oral methotrexate failed to control
her arthritis either because of innate disease resistance
or inadequate gastrointestinal absorption. Oral instead
of subcutaneous route was chosen based on family’s
preferences.
Introduction of anti-TNF-a biologics has altered the
therapeutic approach to inflammatory conditions, over
the last decade. The use of infliximab, a chimeric partly
humanized monoclonal antibody, is well established in
the treatment of both IBD and JIA in children. Placing a
permanent intravenous catheter in a patient with DEB is
very likely to have detrimental results given the high
risk of secondary infection and sepsis. Adalimumab, a
fully humanized IgG1 anti-TNF-a monoclonal antibody,
is an approved drug for the treatment of JIA. Its use in
IBD in adults is well documented and it has been
recently reported as a safe and effective treatment for
children with Crohn’s disease [5]. In our case, it was
considered as a safe alternative given its benefit for sub-
cutaneous administration.
The patient remains asymptomatic for over 12 months
and both her IBD and arthritis are well controlled.
Nevertheless, immunological long-term complications of
anti-TNF-a biologics are yet to be determined. Addi-
tionally, the long term risk of developing skin cancer
reported in adults on anti-TNF treatment needs to be
kept in mind especially in this case since patients with
RDEB are more prone to epithelial squamous cell carci-
nomas; hence closed surveillance with regular skin
examination is required.
The occurrence in our patient of RDEB, IBD and JIA
is difficult toexplain. Acquired EB has been linked with
autoimmune conditions suchas IBD, rheumatoid arthri-
tis, and Hashimoto’s thyroiditis with the pathophysiolo-
gical mechanism involving production of IgG antibodies
against an epitope of collagen type VII, the main com-
ponent of anchoring fibrils at the dermo-epidermal
junction (DEJ), and the mutated protein in dystrophic
forms of EB [6]. Even in the absence of collagen VII in
the joints, molecular mimicry might explain why these
patients develop autoimmune arthritis. Similarly, in our
case, it may be that fragility at the DEJ in RDEB leads to
exposure of normally hidden autoantigens that subse-
quently trigger an immune reaction in other tissues
including the joints.
Conclusion
We have presented the unique case of a child with
RDEB who also developed IBD and persistent oligoarti-
cular JIA and discussed the important issues that need
to be taken into account when assessing and managing
patients with such complex conditions. Every step has
to be cautious and constantly balanced against the risks
associated with the intervention, as well as the long-
term effects on the patient’s quality of life.
Key points
1. Children with rare diseases are similarly prone to
develop other commoner conditions compared to
the general population; therefore the newly pre-
sented persistent symptoms should be cautiously
reviewed.
2. Treatment of patients with complex medical needs
has to be guided primarily by the impact on the
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treatment affect or improve their life expectancy.
3. Multi-disciplinary team approach and effective
communication of treatment options with the
patient and family, facilitates decision making and
improves the outcome.
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Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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